Andrew J. Davis

Andrew J. Davis

Auto-generated profile, based on publicly available information

Andrew J. Davis

Sandoz Institute for Medical Research, London

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2001 in Neuropharmacology
Verified
Journal Article
Closed access
KWK Walker
K Walker
ARA Reeve
A Reeve
MBM Bowes
M Bowes
JWJ Winter
J Winter
GWG Wotherspoon
G Wotherspoon
LUL Urban
L Urban

1 April 1993 in Journal of Animal Ecology
Verified
Journal Article
Closed access
ADAndrew J. Davis
Andrew J. Davis
IHIlkka Hanski
Ilkka Hanski
YCYves Cambefort
Yves Cambefort

1 January 2001 in Neuropharmacology
Verified
Journal Article
Closed access
KWK Walker
K Walker
MBM Bowes
M Bowes
MPM Panesar
M Panesar
ADA Davis
A Davis
CGC Gentry
C Gentry
RKR Kuhn
R Kuhn

1 September 1994 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
ADA.J. Davis
A.J. Davis
MPM.N. Perkins
M.N. Perkins
Interleukin‐1β (IL‐1β), IL‐2 and IL‐8 induced a mechanical hyperalgesia following intra‐articular (i.artic.) injection into rat knee joints, whereas IL‐6 and tumour necrosis factor α (TNF‐α) were without effect. Co‐administration of IL‐1 receptor antagonist (0.1 μg) with IL‐1β (1 u), IL‐2 (10 u) or IL‐8 (0.1 u) prevented the subsequent development of the hyperalgesia. Co‐administration of desArg9Leu8BK (0.5–5 nmol) with IL‐1β (1 u), IL‐2 (10 u) or IL‐8 (0.1 u) reduced the level of hyperalgesia at 1, 4 and 6h post administration, whereas Hoe 140 (5 pmol) antagonized the hyperalgesia only at the 1 h time point. Intravenous administration of desArg9Leu8BK (10 nmol kg−1) or Hoe 140 (100 pmol kg−1) following IL‐1β (1 u), IL‐2 (10 u), or IL‐8 (0.1 u) reversed the subsequent hyperalgesia. Administration of desArg9BK into joints 24 h after pre‐treatment with IL‐1β (1 u) produced analgesia at low doses (50 pmol) and hyperalgesia at a higher dose (0.5 nmol). Both these effects were blocked by desArg9Leu8BK (0.5 nmol). Administration of desArg9BK (0.5 nmol i.artic.) to animals 24 h after pre‐treatment with IL‐2 (1–100 u) or IL‐8 (0.1–10 u) had no effect on the load tolerated by the treated joint. Administration of indomethacin (1 mg kg−1, s.c.) prior to IL‐1β (1 u i.artic.) prevented the development of hyperalgesia. Administration of desArg9BK (5 pmol‐0.5 nmol, i.artic.) to animals 24 h after indomethacin and IL‐1β pretreatment had no effect on the load tolerated by the treated joint. These data suggest that both bradykinin B1 and B2 receptors are involved in the induction and maintenance of cytokine‐induced hyperalgesia. They also show that the induction of B1 receptor‐mediated hyperalgesia requires both cyclo‐oxygenase products and IL‐1 in vivo.

30 January 2000 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
GBGillian M Burgess
Gillian M Burgess
MPMartin N Perkins
Martin N Perkins
HRHumphrey P Rang
Humphrey P Rang
ECElizabeth A Campbell
Elizabeth A Campbell
MBMichael C Brown
Michael C Brown
GBGraham C Bloomfield
Graham C Bloomfield

14 July 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EDEdward K. Dziadulewicz
Edward K. Dziadulewicz
SBStuart Bevan
Stuart Bevan
CBChristopher T. Brain
Christopher T. Brain
PCPaul R. Coote
Paul R. Coote
ACAndrew J. Culshaw
Andrew J. Culshaw
JZJiri Zadrobilek
Jiri Zadrobilek